BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER® Sirolimus-eluting Coronary Stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, AK.
